{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:39:06Z","timestamp":1792287546837,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ymthe.2019.07.012","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T20:41:34Z","timestamp":1564087294000},"page":"2005-2017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Exons 45\u201355 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene"],"prefix":"10.1016","volume":"27","author":[{"given":"Yusuke","family":"Echigoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji Rowel Q.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyanna","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu","family":"Trieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Mizobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Mamchaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tanihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin\u2019ichi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mouly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Duddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2019.07.012_bib1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2019.07.012_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/jpm8040041","article-title":"Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges","volume":"8","author":"Echigoya","year":"2018","journal-title":"J.\u00a0Pers. Med."},{"key":"10.1016\/j.ymthe.2019.07.012_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2019.07.012_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"10.1016\/j.ymthe.2019.07.012_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymthe.2019.07.012_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2019.07.012_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy","volume":"10","author":"Komaki","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2019.07.012_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/nat.2013.0451","article-title":"Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides","volume":"24","author":"Echigoya","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2019.07.012_bib9","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/jnnp-2013-306350","article-title":"Dystrophin levels and clinical severity in Becker muscular dystrophy patients","volume":"85","author":"van den Bergen","year":"2014","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2019.07.012_bib10","doi-asserted-by":"crossref","first-page":"32439","DOI":"10.1038\/srep32439","article-title":"Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies","volume":"6","author":"Bello","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2019.07.012_bib11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/jhg.2016.152","article-title":"Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy","volume":"62","author":"Nakamura","year":"2017","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.ymthe.2019.07.012_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3233\/JND-170225","article-title":"Characteristics of Japanese Patients with Becker Muscular Dystrophy and Intermediate Muscular Dystrophy in a Japanese National Registry of Muscular Dystrophy (Remudy): Heterogeneity and Clinical Variation","volume":"5","author":"Mori-Yoshimura","year":"2018","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2019.07.012_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/humu.20428","article-title":"Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy","volume":"28","author":"B\u00e9roud","year":"2007","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2019.07.012_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/mus.21193","article-title":"Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion","volume":"39","author":"Ferreiro","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2019.07.012_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jocn.2006.12.012","article-title":"Follow-up of three patients with a large in-frame deletion of exons 45-55 in the Duchenne muscular dystrophy (DMD) gene","volume":"15","author":"Nakamura","year":"2008","journal-title":"J.\u00a0Clin. Neurosci."},{"key":"10.1016\/j.ymthe.2019.07.012_bib16","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1093\/brain\/awr291","article-title":"Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials","volume":"134","author":"Anthony","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2019.07.012_bib17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/jnnp-2012-304729","article-title":"Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy","volume":"85","author":"van den Bergen","year":"2014","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymthe.2019.07.012_bib18","first-page":"9","article-title":"Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene","volume":"34","author":"Taglia","year":"2015","journal-title":"Acta Myol."},{"key":"10.1016\/j.ymthe.2019.07.012_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2350-9-105","article-title":"Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy","volume":"9","author":"van Vliet","year":"2008","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.ymthe.2019.07.012_bib20","doi-asserted-by":"crossref","first-page":"13763","DOI":"10.1073\/pnas.1204638109","article-title":"Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery","volume":"109","author":"Aoki","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.07.012_bib21","doi-asserted-by":"crossref","first-page":"e0197084","DOI":"10.1371\/journal.pone.0197084","article-title":"Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2019.07.012_bib22","doi-asserted-by":"crossref","first-page":"e0120058","DOI":"10.1371\/journal.pone.0120058","article-title":"In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy","volume":"10","author":"Echigoya","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2019.07.012_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaneurol.2013.4908","article-title":"Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping","volume":"71","author":"Anthony","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2019.07.012_bib24","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1038\/mtna.2014.76","article-title":"Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice","volume":"4","author":"Echigoya","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2019.07.012_bib25","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","article-title":"Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy","volume":"25","author":"Echigoya","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.07.012_bib26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2144\/000114167","article-title":"Lessons learned from vivo-morpholinos: How to avoid vivo-morpholino toxicity","volume":"56","author":"Ferguson","year":"2014","journal-title":"Biotechniques"},{"key":"10.1016\/j.ymthe.2019.07.012_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-4939-6817-6_11","article-title":"Use of Translation Blocking Morpholinos for Gene Knockdown in Giardia lamblia","volume":"1565","author":"Krtkov\u00e1","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2019.07.012_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4939-6817-6_3","article-title":"Aggregation and Disaggregation of Morpholino Oligomers in Solution","volume":"1565","author":"Chow","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2019.07.012_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17101722","article-title":"Endogenous Multiple Exon Skipping and Back-Splicing at the DMD Mutation Hotspot","volume":"17","author":"Suzuki","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2019.07.012_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbrc.2018.09.039","article-title":"Truncated dystrophin ameliorates the dystrophic phenotype of mdx mice by reducing sarcolipin-mediated SERCA inhibition","volume":"505","author":"Tanihata","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2019.07.012_bib31","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2019.07.012_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1089\/nat.2012.0368","article-title":"Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs","volume":"22","author":"Yokota","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2019.07.012_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ymthe.2018.10.011","article-title":"Efficacy of multi-exon skipping treatment in Duchenne muscular dystrophy dog model neonates","volume":"27","author":"Lim","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.07.012_bib34","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1073\/pnas.1613203114","article-title":"Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy","volume":"114","author":"Echigoya","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.07.012_bib35","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41582-018-0033-8","article-title":"Why dystrophin quantification is key in the eteplirsen saga","volume":"14","author":"Aartsma-Rus","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2019.07.012_bib36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/JND-170218","article-title":"Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR\/Cas9 Gene Editing Therapy","volume":"4","author":"Young","year":"2017","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2019.07.012_bib37","doi-asserted-by":"crossref","first-page":"e0193289","DOI":"10.1371\/journal.pone.0193289","article-title":"A dystrophic Duchenne mouse model for testing human antisense oligonucleotides","volume":"13","author":"Veltrop","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2019.07.012_bib38","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCGENETICS.109.867242","article-title":"Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in becker muscular dystrophy","volume":"2","author":"Kaspar","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ymthe.2019.07.012_bib39","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.nmd.2018.09.001","article-title":"Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies\u2014Still a possible treatment modality?","volume":"28","author":"Dombernowsky","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2019.07.012_bib40","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1093\/hmg\/dds176","article-title":"Variable phenotype of del45-55 Becker patients correlated with nNOS\u03bc mislocalization and RYR1 hypernitrosylation","volume":"21","author":"Gentil","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2019.07.012_bib41","doi-asserted-by":"crossref","first-page":"29531","DOI":"10.1074\/jbc.M115.680660","article-title":"Structural Basis of Neuronal Nitric-oxide Synthase Interaction with Dystrophin Repeats 16 and 17","volume":"290","author":"Molza","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2019.07.012_bib42","doi-asserted-by":"crossref","first-page":"35375","DOI":"10.1074\/jbc.274.50.35375","article-title":"Utrophin lacks the rod domain actin binding activity of dystrophin","volume":"274","author":"Amann","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2019.07.012_bib43","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jmb.2009.04.025","article-title":"Mapping of the lipid-binding and stability properties of the central rod domain of human dystrophin","volume":"389","author":"Legardinier","year":"2009","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ymthe.2019.07.012_bib44","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/hmg\/ddu537","article-title":"Becker muscular dystrophy severity is linked to the structure of dystrophin","volume":"24","author":"Nicolas","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2019.07.012_bib46","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1517\/14712598.2012.693469","article-title":"Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?","volume":"12","author":"Yokota","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2019.07.012_bib47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2019.07.012_bib48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.omtn.2018.10.004","article-title":"Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy","volume":"13","author":"Lee","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2019.07.012_bib49","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1242\/dev.001115","article-title":"Controlling morpholino experiments: don\u2019t stop making antisense","volume":"135","author":"Eisen","year":"2008","journal-title":"Development"},{"key":"10.1016\/j.ymthe.2019.07.012_bib50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2044-5040-1-34","article-title":"Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders","volume":"1","author":"Mamchaoui","year":"2011","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ymthe.2019.07.012_bib51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ymthe.2004.05.031","article-title":"Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides","volume":"10","author":"Bremmer-Bout","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.07.012_bib52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbrc.2004.12.191","article-title":"A new model mouse for Duchenne muscular dystrophy produced by 2.4 Mb deletion of dystrophin gene using Cre-loxP recombination system","volume":"328","author":"Kudoh","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619303259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619303259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:55:41Z","timestamp":1761501341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001619303259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1525001619303259"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.012","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exons 45\u201355 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}